Ambrosia Biosciences Secures $100 Million Series B Financing for Advancement of GLP-1 Candidate

Ambrosia Biosciences Inc. has raised an oversubscribed $100 million Series B financing to propel its oral small molecule GLP-1 candidate and other innovative cardiometabolic programs into clinical development. The funding was co-led by new investors and supported by existing and additional new investors.